HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BE 13793C
from an actinomycetes; structure given in first source
Also Known As:
12,13-dihydro-1,11-dihydroxy-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione; 5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12,13-dihydro-1,11-dihydroxy-; BE-13793C; J 104303; J-104303
Networked:
2
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Indoles: 200
Carbazoles: 32
BE 13793C: 2
3-Ring Heterocyclic Compounds
Carbazoles: 32
BE 13793C: 2
Related Diseases
1.
Neoplasms (Cancer)
04/01/1997 - "
DNA topoisomerase I has been shown to be an important therapeutic target in cancer chemotherapy for the camptothecins as well as for indolocarbazole antibiotics such as BE-13793C and its synthetic derivatives NB-506 and ED-110 [Yoshinari et al. (1993) Cancer Res. 53, 490-494].
"
2.
Leukemia
07/01/1991 - "
BE-13793C showed strong inhibitory activity against topoisomerases I and II and inhibited the growth of doxorubicin-resistant or vincristine-resistant P388 murine leukemia cell lines, as well as their parent P388 cell line.
"
Related Drugs and Biologics
1.
Vincristine (Oncovin)
2.
Doxorubicin (Adriamycin)
3.
Type I DNA Topoisomerases (Topoisomerase I)
4.
Anti-Bacterial Agents (Antibiotics)
5.
NB 506
6.
ED 110
Related Therapies and Procedures
1.
Drug Therapy (Chemotherapy)